Denali therapeutics announces appointment of erik harris to board of directors

South san francisco, calif., feb. 07, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced that erik harris has joined the board of directors. mr. harris' extensive biotech leadership and pharmaceutical experience includes 20 years in all aspects of commercial operations and achieving successful product launches in multiple therapeutic areas, including neurological and rare diseases.
DNLI Ratings Summary
DNLI Quant Ranking